Invest Victoria and the Victorian Government continues to attract global investment to Parkville - a world-leading biomedical precinct, as more companies choose to call Melbourne, Australia home.

Photo of: Zoetis CEO visiting Zoetis Australia team

Victoria has now secured an investment from major global animal health company Zoetis Australia, valued at up to $350 million.

The agreement includes a capital investment to help establish sovereign manufacturing capabilities, the creation of up to 95 jobs and the acquisition of the majority of the former CSL site at Poplar Road – which the Government acquired to further its vision for the Parkville Precinct as a world-leading biomedical centre for innovation and advanced manufacturing.

Securing Zoetis Australia in Victoria will enhance Australia’s sovereign capabilities within the health technology sector, ensuring Australia’s livestock and domestic animal industries have access to life-saving vaccines, innovative new products and diagnostic tools.

Parkville is one of the world's leading health technology clusters, home to companies and researchers paving the way to develop cutting edge medical and biotechnologies and pharmaceutical products.

CSL’s operations in Australia and the region continue to grow, with a major expansion of its Broadmeadows plasma fractionation facility, the establishment of its recently opened Elizabeth Street global head office and innovation labs, and the development of a new purpose-built facility in Melbourne Airport Business Park at Tullamarine.

When the Metro Tunnel opens a year ahead of schedule in 2025, the Parkville precinct will be serviced by the new Parkville Station – providing faster connections to world-class jobs, education and healthcare for millions of Victorians.

Learn more about Melbourne's Biomedical Precinct.

To explore opportunities for investing in our world class medical research sector, contact us.